Holder evidence
50
SEC ownership of Tvardi Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001346830.
Lead holder
Sporos Bioventures LLC
13D/G signal
Sporos Bioventures LLC
Latest evidence
31 Mar 2026
- CIK
- 0001346830
- Symbol
- TVRD on Nasdaq
- Location
- Sugar Land, TX
- SEC evidence mix
- 13D/G, 13F, and 3/4/5
- Lead holder
- Sporos Bioventures LLC
- Latest large-stake holder
- Sporos Bioventures LLC
- Latest evidence date
- 31 Mar 2026
Issuer identity
Ownership snapshot
Ownership snapshot
Top shareholders of Tvardi Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Lead holder
Sporos Bioventures LLC
13D/G signal
Sporos Bioventures LLC
Evidence rows
50
Latest as of
31 Mar 2026
13D/G
13F
3/4/5
Lead comparable stake: 9%
13D/G row: Sporos Bioventures LLC
Showing 1-8 of 50 holder rows.
Rank 1 holder
Sporos Bioventures LLC
13D/G
- Ownership
- 9%
- Position
- $19.54M
Rank 2 holder
Solas Tvardi Sidecar LLC
13D/G
- Ownership
- 8.1%
- Position
- $4.05M
Rank 3 holder
Slate Path Capital LP
13D/G
13F
- Ownership
- 7.5%
- Position
- $19.26M
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Sporos Bioventures LLC |
13D/G
|
9%
|
$19,544,812
837,636 shares
|
$0 | 15 Apr 2025 |
| Solas Tvardi Sidecar LLC |
13D/G
|
8.1%
|
$4,050,047
761,287 shares
|
$0 | 15 Apr 2025 |
| Slate Path Capital LP |
13D/G
13F
Company
|
7.5%
|
$19,257,627
704,118 shares
|
$0 | 30 Jun 2025 |
| David J. Tweardy |
13D/G
|
7%
|
$3,470,757
652,398 shares
|
$0 | 15 Apr 2025 |
| Ronald A. DePinho |
13D/G
|
4.5%
|
$1,939,164
426,190 shares
|
$0 | 31 Dec 2025 |
| Samuel D. Tweardy |
13D/G
|
3.4%
|
$7,365,343
315,658 shares
|
-$14,730,686 | 07 Jul 2025 |
| Vifor (International) Ltd |
3/4/5
13D/G
10%+ Owner
|
2.2%
from 13D/G
|
$9,024,059
7,396,770 shares
|
— | 20 Oct 2021 |
| BlackRock, Inc. |
13F
Company
|
4.1%
|
$1,234,077
388,075 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 31 May 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 28 reporting-owner rows connected to Tvardi Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
28
Lead holder
CSL LTD
Net 12M change
$0
Latest report
29 Jan 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| CSL LTD | 10%+ Owner | $9,024,059 | Mixed | 09 Aug 2022 | ||
| Vifor (International) Ltd | 10%+ Owner | $9,024,059 | Mixed | 20 Oct 2021 | ||
| Shaheen Wirk | Director | $2,225,966 | Mixed | 17 Apr 2025 | ||
| Wallace L. Hall Jr. | Director | $1,250,632 | Mixed | 17 Apr 2025 | ||
| Chalmers Derek T. | President & CEO, Director | $1,209,514 | Mixed | 07 Sep 2021 | ||
| Martin Vogelbaum | Director | $308,255 | Mixed | 04 Jun 2024 | ||
| Jeffrey L. Ives | Director | $148,864 | Mixed | 04 Jun 2024 | ||
| Lisa von Moltke | Director | $137,257 | Mixed | 04 Jun 2024 | ||
| Helen M. Boudreau | Director | $112,985 | Mixed | 04 Jun 2024 | ||
| Frederique Ph.D. Menzaghi | Chief Scientific Off,Svp R&D | $91,986 | Mixed | 01 Feb 2024 | ||
| Harrison M. Bains Jr. | Director | $70,074 | Mixed | 01 Jun 2023 | ||
| Christopher Posner | PRESIDENT AND CEO, Director | $62,268 | Filing P/S | 28 Feb 2025 | ||
| Thomas Charles Reilly | Chief Financial Officer | $46,129 | Mixed | 03 Mar 2022 | ||
| Joana Goncalves | Chief Medical Officer | $44,293 | Filing P/S | 05 Apr 2024 | ||
| Scott Terrillion | Sec'y; Chief Compliance & G.C. | $34,224 | Filing P/S | 28 Feb 2025 | ||
| Richard Makara | VP, Head of Accting;Controller | $16,571 | Mixed | 15 Jun 2022 | ||
| Ryan D. Maynard | Chief Financial Officer | $7,425 | Mixed | 08 Feb 2024 | ||
| Samuel D. Tweardy | 10%+ Owner | Mixed | 07 Jul 2025 | |||
| Michael S. Wyzga | Director | Mixed | 17 Apr 2025 | |||
| Sujal Shah | Director | Mixed | 17 Apr 2025 |
Recent insider transactions for Tvardi Therapeutics, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Reported value | Reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Avi Daniel Conn | TVRD | Employee Stock Option (right to buy) | Award | 45,000 | 45,000 | 29 Jan 2026 | Direct | |||
| Stephen Paul O'Brien | TVRD | Employee Stock Option (right to buy) | Award | 15,000 | 15,000 | 29 Jan 2026 | Direct | |||
| Imran Nizamudin Alibhai | TVRD | Employee Stock Option (right to buy) | Award | 115,000 | 115,000 | 29 Jan 2026 | Direct | |||
| John Saewook M.d. Kauh | TVRD | Employee Stock Option (right to buy) | Award | 45,000 | 45,000 | 29 Jan 2026 | Direct | |||
| Stephen Paul O'Brien | TVRD | Employee Stock Option (right to buy) | Award | 4,000 | 4,000 | 16 Dec 2025 | Direct | |||
| John Saewook M.d. Kauh | TVRD | Employee Stock Option (right to buy) | Award | 17,500 | 17,500 | 16 Dec 2025 | Direct | |||
| Avi Daniel Conn | TVRD | Employee Stock Option (right to buy) | Award | 17,500 | 17,500 | 16 Dec 2025 | Direct | |||
| Imran Nizamudin Alibhai | TVRD | Employee Stock Option (right to buy) | Award | 47,500 | 47,500 | 16 Dec 2025 | Direct | |||
| Samuel D. Tweardy | TVRD | Common Stock | Other | -100% | -631,316 | 0 | 07 Jul 2025 | By Trust |
* indicates a reported price that failed the local validity check.